Systematic analysis of cellular cross-talk reveals a role for SEMA6D-TREM2 regulating microglial function in

Ricardo D'Oliveira Albanus1,2,3, Gina M Finan4,5, Logan Brase1,3

  • 1Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63130, USA.

PubMed

Insights

Cellular communication disruptions involving TREM2 and SEMA6D impact Alzheimer's disease (AD) progression. Loss of SEMA6D signaling impairs microglial function and amyloid-beta clearance in AD brains.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Cellular cross-talk is vital for brain health and implicated in neurodegenerative diseases like Alzheimer's disease (AD).
  • Understanding dysregulated cellular communication networks is crucial for identifying AD pathogenesis and therapeutic targets.

Purpose of the Study:

  • To reconstruct and analyze cellular cross-talk networks in the human brain to identify dysregulations associated with Alzheimer's disease (AD).
  • To investigate the role of TREM2 and SEMA6D in neuron-microglia communication within the context of AD.

Main Methods:

  • Reconstruction of cellular cross-talk networks using single-nucleus transcriptional profiles from human brain donors.
  • Spatial transcriptomics and tissue immunostaining to analyze gene network activation and protein localization in human brain tissue.
  • Validation using induced pluripotent stem cell-derived microglia from TREM2 knockout models.

Main Results:

  • Identified a neuron-microglia cross-talk network mediated by TREM2 and neuronal SEMA6D, disrupted in late-stage AD.
  • Observed SEMA6D-TREM2 network activation near amyloid-beta (Aβ) plaques, with SEMA6D colocalizing with plaques and microglia.
  • Found decreased SEMA6D abundance with disease stage, correlating with reduced microglial activation and impaired Aβ clearance.
  • Demonstrated that SEMA6D induces microglial activation and Aβ phagocytosis in a TREM2-dependent manner.

Conclusions:

  • Characterizing cellular cross-talk networks provides critical insights into AD biology and genetic risk factors.
  • The SEMA6D-TREM2 pathway is a key mediator of neuron-microglia communication, with its disruption contributing to AD.
  • This study identifies novel therapeutic targets and pathways for Alzheimer's disease intervention.